Proteomic analysis of plasma exosome protein in patients with type 2 diabetes mellitus
ZHANG Li1,2, HUANG Cai-yan2, FENG Tian-yuan2, YANG Shu-cai2, LIU Hui2, ZHANG Yang2, WANG Ge-fei1
1. Center of Pathogen Biology and Immunology, Shantou University Medical College, Shantou, Guangdong 515041, China; 2. Pingshan District People's Hospital/Pingshan General Hospital of Southern Medical University, Shenzhen, Guangdong 518118, China
Abstract：Objective To explore the difference in plasma exosomal proteome between type 2 diabetes mellitus (T2DM) patients and healthy subjects, and to provide a scientific basis for early diagnosis, prognosis judgment and treatment targets. Methods Blood plasma samples were collected from 6 T2DM patients and 6 healthy subjects at the same time. Exosomes were isolated by qEV original size exclusion column from plasma, and protein was extracted. Quantitative analysis to identify the difference in plasma exosomal protein expression was performed by liquid chromatography-mass spectrometry (LC-MS), and the results were analyzed with various bioinformatic tools to determine changes in activity features, subcellular localization and cellular functions of the identified proteins. Results A total of 948 quantifiable protein molecules were obtained, 23 were up-regulated in the T2DM patients as compared with the healthy subjects, and 124 were down-regulated. Among the up-regulated exosome components, many proteins including several complement component molecules were inflammation-associated proteins. Conclusion There is a certain difference in the expression of plasma exosomal proteins between type 2 diabetic patients and normal healthy people. This difference in exosomal protein composition may provide new candidate molecules for the early diagnosis of type 2 diabetes mellitus and provide evidence for the elucidation of its pathogenesis.
[1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition[J]. Diabetes Res Clin Pract, 2019,157:107843. [2] 张晓妙,魏琳,卢乐. 2型糖尿病患者营养状况筛查及营养不良相关因素分析[J]. 实用预防医学, 2021,28(5):605-607. [3] Hu C,Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication[J]. Diabetes, 2018,67(1):3-11. [4] 窦梅,马爱国. 胰岛素抵抗主要原因及机制的研究进展[J]. 国外医学(卫生学分册), 2009,36(3):174-179. [5] 孙梦婷,李慧芹,谭滇湘,等. 外泌体在肺部炎症性疾病中的研究进展[J]. 实用预防医学, 2021,28(1):124-129. [6] Castano C,Novials A,Parrizas M. Exosomes and diabetes[J]. Diabetes Metab Res Rev, 2019,35(3):e3107. [7] Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: challenges and opportunities[J]. J Cell Physiol, 2018,233(9):6370-6380. [8] 解修峰,史志周. 肿瘤及其微环境源性外泌体miRNAs在致癌机制、肿瘤诊断和治疗中的研究进展[J]. 基础医学与临床, 2017,37(9):1326-1330. [9] 覃思华,郑磊. 外泌体蛋白质组学研究进展[J]. 临床检验杂志, 2016,34(12):927-930. [10] Zhang H, Liu J, Qu D, et al. Serum exosomes mediate delivery of arginase 1 as a novel mechanism for endothelial dysfunction in diabetes[J]. Proc Natl Acad Sci USA, 2018,115(29):E6927-E6936. [11] Deng ZB, Poliakov A, Hardy RW, et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance[J]. Diabetes, 2009,58(11):2498-2505. [12] Jalabert A, Vial G, Guay C, et al. Exosome-like vesicles released from lipid-induced insulin-resistant muscles modulate gene expression and proliferation of beta recipient cells in mice[J]. Diabetologia, 2016,59(5):1049-1058. [13] Kranendonk ME, de Kleijn DP, Kalkhoven E, et al. Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease[J]. Cardiovasc Diabetol, 2014,13:37. [14] 陈明,尹晓晨,段雨劼,等. 儿童青少年脂肪细胞因子等指标与超重和肥胖关系研究[J]. 实用预防医学, 2020,27(10):1163-1167. [15] Shoelson SE,Lee J,Goldfine AB. Inflammation and insulin resistance[J]. J Clin Invest, 2006,116(7):1793-1801. [16] Phieler J, Garcia-Martin R, Lambris JD, et al. The role of the complement system in metabolic organs and metabolic diseases[J]. Semin Immunol, 2013,25(1):47-53. [17] Muscari A, Antonelli S, Bianchi G, et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population[J]. Diabetes Care, 2007,30(9):2362-2368. [18] Copenhaver M, Yu CY, Hoffman RP. Complement components, C3 and C4, and the metabolic syndrome[J]. Curr Diabetes Rev, 2019,15(1):44-48. [19] Osborn O, Oh DY, McNelis J, et al. G protein-coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice[J]. J Clin Invest, 2012,122(7):2444-2453. [20] Mamane Y, Chung CC, Lavallee G, et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation[J]. Diabetes, 2009,58(9):2006-2017.
2022, Vol. 29 
